AlloVir (ALVR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALVR AlloVir

Watchlist

0.550
+0.000+0.02%

Close Nov 25 16:00 ET

0.533
-0.017-3.09%

Post 20:01 ET

63.55MMarket Cap-625P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

AlloVir | 10-Q: Q3 2024 Earnings Report
SECNov 12 16:03 ET · Announcements
AlloVir and Kalaris Enter Merger to Advance Retinal Disease Therapies
Yahoo FinanceNov 11 10:44 ET
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business WireNov 8 09:39 ET
Sector Update: Health Care Stocks Edge Higher Premarket Friday
MT NewswiresNov 8 09:07 ET
Sector Update: Health Care
MT NewswiresNov 8 08:52 ET
Express News | Allovir - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Kalaris Termination Fee of $3.5 Mln
ReutersNov 8 08:41 ET

Comments

Jaguar8

Nov 8 12:30

NEWS

$AlloVir (ALVR.US)$
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
AlloVir has announced a merger with Kalaris Therapeutics in an all-stock transaction. The combined company will focus on developing TH103, a novel anti-VEGF therapy for retinal diseases, invented by Dr. Napoleone Ferrara. After the merger, pre-Merger AlloVir stockholders will own 25.05% and Kalaris stockholders 74.95% of the combined company. ...

Moomoo AI

Dec 28, 2023 07:04

AlloVir's reassuring cash runway contrasts with worrying cash burn in relation to its market cap, raising concerns of funding stress and heightening stock uncertainty.

We're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Trytosaveabit

Dec 22, 2023 06:22

Resume trade at 7:30AM est TIMBER???

$AlloVir (ALVR.US)$ Hehehe! SUX! But could offer a bottom buy then see if a big Pharmaceutical company offers to buy the rest of their research?

Trytosaveabit

Dec 22, 2023 06:11

This could get ugly when halt comes off

$AlloVir (ALVR.US)$ AlloVir Says It Will Discontinue Its Three Phase 3 Posoleucel Studies Following Separate, Pre-planned DSMB Futility Analyses Concluding Studies Were Unlikely To Meet Primary Endpoints
Moomoo 24/7· 1 min ago